Refractory Escherichia Coli Pneumonia: A Case Report

What Is A COPD Exacerbation?

Chronic obstructive pulmonary disease (COPD) is a persistent respiratory disease that may cause long-term, progressive lung damage. Acute exacerbations are when a person's respiratory symptoms significantly worsen.

People with chronic obstructive pulmonary disease (COPD) may experience episodes of severe, acute symptoms that require therapy. An acute flare-up is a sudden, short-term onset of symptoms.

These are known as exacerbations and may:

contribute to COPD progression

increase healthcare costs

lead to a change in your treatment plan and medication

cause irreversible lung damage

lower your quality of life

increase your risk of hospitalization and death

The average person with COPD experiences between 0.85–1.3 exacerbations a year. Exacerbation symptoms may take 2–3 days to develop, and periods may last between 7 and 14 days. However, according to research, lung function may not fully return to pre-exacerbation levels after 8 weeks.

It's estimated that more than 10 million healthcare visits per year in the United States are due to COPD exacerbations. In 2019, according to the Centers for Disease Control and Prevention (CDC), COPD was the fourth leading cause of death.

Exacerbation symptoms may differ from typical COPD symptoms, and they're often more severe. The most common exacerbation symptom is dyspnea, which is shortness of breath or difficulty breathing.

Other signs and symptoms may include:

breathing in a fast, shallow pattern

coughing

feeling excessively sleepy or confused

lower oxygen levels than the clinical expectation

increased sputum production, which is often yellow, green, tan, or even blood-tinged

wheezing and chest tightness

It's important to speak with a doctor if you recognize early indications or experience any of these signs or symptoms. One exacerbation may be enough to increase the frequency, duration, and severity of episodes.

Some COPD exacerbation symptoms require immediate emergency care. Examples include:

A COPD exacerbation increases the current inflammation of your airway and lungs. This may be triggered by:

viral infections, such as those caused by human rhinoviruses, which include the common cold

bacterial tracheobronchial infections

smoking

air pollutants and irritants, such as chemical agents, fumes, and dust

chronic bronchitis

There's currently no single test to diagnose a COPD exacerbation. A doctor will assess your symptoms to see whether they stem from a worsening comorbidity, such as pneumonia, osteoporosis, or acute cardiac failure.

They may also ask you to complete a few patient-centered surveys, which may include:

COPD Assessment Test (CAT)

Medical Research Council (mMRC) dyspnea scale

Clinical COPD Questionnaire (CCQ)

St. George's Respiratory Questionnaire (SGRQ)

The doctor will then make a diagnosis based on the questionnaire and the symptom elimination process.

The strongest predictor of an exacerbation occurring is whether you've had one before. But with some COPD exacerbations, there are no known causes, according to the American Thoracic Society.

If you have COPD, it's important to take every step possible to avoid lung infection. Actionable steps can include getting your annual flu shot, getting the annual pneumococcal vaccine, and staying up to date with COVID-19 vaccination. Infections and colds may cause serious complications.

Treatments for COPD exacerbations focus on reducing the effects of the current episode and depend on whether you're hospitalized. Exacerbations may be classified as mild, moderate, or severe.

Home treatments

It is estimated that 80% or more of COPD exacerbations are typically mild or moderate and can be treated at home with medication.

A doctor may prescribe:

Emergency treatments

Some people who experience severe COPD exacerbations may be hospitalized. This might be due to symptom severity, limited support at home, or poor response to initial treatments.

At a hospital, the doctor may provide you with oxygen therapy to support your breathing. The first method is through a venturi mask or nasal cannula, which is known as noninvasive ventilation (NIV).

If your symptoms are very severe, such as involving cardiac or respiratory arrest, or you do not respond well to NIV, the doctor will likely put you on a ventilator. If mechanical ventilation is needed, you'll stay in the intensive care unit until your infection clears or your lungs become less inflamed.

Establishing a COPD treatment plan with a doctor is an important step to help prevent future exacerbations.

Along with taking any prescribed medication, some self-care practices include:

What are the common signs of COPD exacerbation?

The most common indicator of a COPD exacerbation is dyspnea, which is shortness of breath or difficulty breathing. Other common signs are wheezing, chest tightness, and increased mucus.

What does a COPD exacerbation feel like?

A COPD exacerbation is when you experience an episode of severe, acute symptoms. You may experience chest tightness and find it very difficult to catch your breath. You may also notice that you're breathing in a fast, shallow pattern. This might make you feel anxious or excessively tired for a prolonged period of time.

If you're having trouble walking, feeling confused, or have clammy skin, it's important to get medical assistance.

Can COPD exacerbation be treated?

Mild and moderate COPD exacerbations may often be treated at home, while severe episodes might require hospitalization.

At-home treatments can include medications, lifestyle and dietary adjustments, and engaging in and keeping a record of self-care activities.

Hospital treatments might include oxygen therapy, mechanical ventilation, and medications.

COPD exacerbations are very serious. They may cause permanent lung damage, lower your quality of life, and increase your risk of mortality. Having one exacerbation may also heighten the severity and frequency of future exacerbations. Prevention is very important.

If you have COPD or suspect any early signs of an exacerbation, speak with a doctor.

First AI-generated Drug Enters Human Clinical Trials, Targeting Chronic Lung Disease Patients

The first-ever drug generated by artificial intelligence has entered Phase 2 clinical trials, with the first dose successfully administered to a human, Insilico Medicine announced yesterday.

The drug, currently referred to as INS018_055, is being tested to treat idiopathic pulmonary fibrosis (IPF), a rare, progressive type of chronic lung disease. 

The 12-week trial will include participants diagnosed with IPF.

"This drug, which will be given orally, will undergo the same rigorous testing to ensure its effectiveness and safety, like traditionally discovered drugs, but the process of its discovery and design are incredibly new," said Insilico Medicine's CEO Alex Zhavoronkov, PhD, in a statement to Fox News Digital.

FIRST NEW 'QUIT-SMOKING' DRUG IN 20 YEARS SHOWS PROMISING RESULTS IN US TRIAL: 'HOPE AND EXCITEMENT'

"However, with the latest advances in artificial intelligence, it was developed much faster than traditional drugs."

How AI is transforming drug discovery

For any new drug, there are four steps, explained Zhavoronkov, who is based in Dubai.

"First, scientists have to find a 'target,' a biological mechanism that is driving the disease, usually because it is not functioning as intended," he said.

Insilico Medicine's CEO Alex Zhavoronkov, PhD (left), is pictured in the company's AI-run robotics lab in Suzhou, China, which Insilico opened in January 2023.  (Insilico Medicine)

"Second, they need to create a new drug for that target, similar to a puzzle piece, that would block the progression of the disease without harming the patient." 

The third step is to conduct studies — first in animals, then in clinical trials in healthy human volunteers, and finally in patients.

RESEARCHERS USE AI TO UNDERSTAND ALZHEIMER'S DISEASE, IDENTIFY DRUG TARGETS

"If those tests show positive results in helping patients, the drug reaches its fourth and final step — approval by the regulatory agencies for use as a treatment for that disease," said Zhavoronkov.

In the traditional process, he said, scientists find targets by combing through scientific literature and public health databases to look for pathways or genes linked to diseases. 

CEO Alex Zhavoronkov, PhD (left), in the company's AI-run robotics lab in Suzhou, China. "AI allows us to analyze massive quantities of data and find connections that human scientists might miss," he said, "and then 'imagine' entirely new molecules that can be turned into drugs." (Insilico Medicine)

"AI allows us to analyze massive quantities of data and find connections that human scientists might miss, and then 'imagine' entirely new molecules that can be turned into drugs," Zhavoronkov said.

In this case, Insilico used AI both to discover a new target for IPF and then to generate a new molecule that could act on that target. 

AI TECH AIMS TO HELP PATIENTS CATCH DISEASE EARLY, EVEN 'REVERSE THEIR BIOLOGICAL AGE'

The company uses a program called PandaOmics to detect disease-causing targets by analyzing scientific data from clinical trials and public databases.

Once the target was discovered, researchers entered it into Insilico's other tool, Chemistry42, which uses generative AI to design new molecules.

The first drug generated by artificial intelligence has entered Phase 2 clinical trials, with the first dose successfully administered to a human, Insilico Medicine announced. (Insilico Medicine)

"Essentially, our scientists provided Chemistry42 with the specific characteristics they were looking for and the system generated a series of possible molecules, ranked based on their likelihood of success," Zhavoronkov said. 

The chosen molecule, INS018_055, is so named because it was the 55th molecule in the series and showed the most promising activity, he said.

AI-DISCOVERED DRUG SHOWS 'ENORMOUS POTENTIAL' TO TREAT SCHIZOPHRENIA: 'REAL NEED FOR BETTER TREATMENT'

The current treatments for idiopathic pulmonary fibrosis are pirfenidone and nintedanib. 

While these drugs may provide some relief or slow the worsening of symptoms, they do not reverse the damage or stop progression, Zhavoronkov said. 

The Insilico team is hopeful the data from this newly launched clinical trial will confirm their drug's safety and effectiveness. (Insilico Medicine)

They also have unpleasant side effects, most notably nausea, diarrhea, weight loss and loss of appetite.

"There are very few options for people with this terrible condition, and the prognosis is poor — most will die within two to five years of diagnosis," Zhavoronkov explained.

"Our initial studies have indicated that INS018_055 has the potential to address some of the limitations of current therapies."

Next steps

The Insilico team is hopeful the data from this newly launched clinical trial will confirm the drug's safety and effectiveness.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

"If our Phase IIa study is successful, the drug will then go to Phase IIb with a larger cohort of participants," said Hong Kong-based Sujata Rao, M.D., Insilico's chief medical officer, in a statement to Fox News Digital. 

During Phase IIb, the primary objective will be to determine whether there is significant response to the drug, Rao said.

In this case, Insilico used AI to discover a new target for IPF — and then to generate a new molecule that could act on that target.  (Insilico Medicine)

"Then, the drug will go on to be evaluated in a much larger group of patients — typically hundreds — in Phase III studies to confirm the safety and effectiveness before it can be approved by the FDA as a new treatment for patients with that condition," he explained.

One of the biggest challenges with these trials is recruiting patients, Rao said, particularly for a rare disease like idiopathic pulmonary fibrosis. 

CLICK HERE TO GET THE FOX NEWS APP

"Patients need to fulfill certain criteria in order to be considered for trial enrollment," he noted. 

Despite the challenges, Rao said the research team is optimistic that this drug will be ready to go to market — and reach the patients who may benefit from it — in the next few years.

Melissa Rudy is health editor and a member of the lifestyle team at Fox News Digital. 

Chronic Obstructive Pulmonary Disease Pipeline Research 2023: Focus On 65+ Companies And 70+ Pipeline Drugs

DUBLIN, July 14, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023" clinical trials has been added to  ResearchAndMarkets.Com's offering.

Research and Markets Logo

With an extensive focus on 65+ companies and 70+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication.

The report encompasses a comprehensive overview of the pipeline drug profiles, covering both clinical and nonclinical stage products. Additionally, it includes a thorough assessment of therapeutics, considering product type, stage, route of administration, and molecule type. Inactive pipeline products in this space are also highlighted, providing a holistic view of the COPD pipeline landscape.

To provide a comprehensive understanding, this report outlines the present scenario and growth prospects in the COPD field. It offers detailed insights into the disease overview and treatment guidelines for Chronic Obstructive Pulmonary Disease, setting the stage for a deeper exploration of the pipeline landscape.

Furthermore, the report delves into the commercial assessment and clinical assessment of the pipeline products under development. It provides detailed descriptions of each drug, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities.

This encompasses technology, COPD collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters

This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Obstructive Pulmonary Disease Emerging Drugs

Benralizumab: AstraZeneca

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction.

Story continues

Dupilumab: Sanofi

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis.

Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.

Tezepelumab: Amgen

Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma.

TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control.

Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.

SNG001: Synairgen

SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.

GSK3923868: GlaxoSmithKline

GSK3923868, is a PI4kb inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.

Chronic Obstructive Pulmonary Disease: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Obstructive Pulmonary Disease

There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.E. Phase III include, AstraZeneca.

Phases

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Chronic Obstructive Pulmonary Disease Report Insights

Key Players

Sanofi

AstraZeneca

Amgen

Synairgen

GlaxoSmithKline

Eisai

Meridigen Biotech

Chiesi

EmeraMed Limited

Verona Pharma

Tetherex Pharmaceuticals

Mereo BioPharma

Key Products

Lemborexant

UMC119-06

CHF5259

Emeramide

Ensifentrine

SNG001

GSK3923868

Benralizumab

Dupilumab

Tezepelumab

SelK2

BCT197

For more information about this clinical trials report visit https://www.Researchandmarkets.Com/r/w91zlj

About ResearchAndMarkets.ComResearchAndMarkets.Com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.Com For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.Prnewswire.Com/media/539438/Research_and_Markets_Logo.Jpg

Cision

View original content:https://www.Prnewswire.Com/news-releases/chronic-obstructive-pulmonary-disease-pipeline-research-2023-focus-on-65-companies-and-70-pipeline-drugs-301877548.Html

SOURCE Research and Markets

---